Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynaecology and Reproductology, 199034 Saint-Petersburg, Russia.
Bioinformatics Institute, 197342 Saint-Petersburg, Russia.
Genes (Basel). 2022 Jun 30;13(7):1176. doi: 10.3390/genes13071176.
Type 2 diabetes (T2D) is a common chronic disease whose etiology is known to have a strong genetic component. Standard genetic approaches, although allowing for the detection of a number of gene variants associated with the disease as well as differentially expressed genes, cannot fully explain the hereditary factor in T2D. The explosive growth in the genomic sequencing technologies over the last decades provided an exceptional impetus for transcriptomic studies and new approaches to gene expression measurement, such as RNA-sequencing (RNA-seq) and single-cell technologies. The transcriptomic analysis has the potential to find new biomarkers to identify risk groups for developing T2D and its microvascular and macrovascular complications, which will significantly affect the strategies for early diagnosis, treatment, and preventing the development of complications. In this article, we focused on transcriptomic studies conducted using expression arrays, RNA-seq, and single-cell sequencing to highlight recent findings related to T2D and challenges associated with transcriptome experiments.
2 型糖尿病(T2D)是一种常见的慢性疾病,其病因被认为具有很强的遗传成分。标准的遗传方法虽然可以检测到一些与疾病相关的基因变异和差异表达基因,但不能完全解释 T2D 的遗传因素。过去几十年中基因组测序技术的爆炸式增长为转录组研究和新的基因表达测量方法(如 RNA 测序(RNA-seq)和单细胞技术)提供了非凡的动力。转录组分析有可能找到新的生物标志物,以确定发生 T2D 及其微血管和大血管并发症的风险群体,这将对早期诊断、治疗和预防并发症的发展策略产生重大影响。在本文中,我们重点介绍了使用表达谱芯片、RNA-seq 和单细胞测序进行的转录组研究,以突出与 T2D 相关的最新发现和与转录组实验相关的挑战。